Bristol-Myers Squibb Company (BMY) — Fair Value Analysis

Base-case fair value (P50): $59.76 · Current price: $58.13 · Verdict: Fairly Valued

The Verdict on BMY

Bristol Myers Squibb (BMY), a key player in the Healthcare sector, currently trades at $58.13. Our Monte Carlo simulations, which model thousands of future scenarios, suggest a median fair value (P50) of $59.76. This indicates that BMY is presently Fairly Valued, with a marginal +2.8% upside to its median probabilistic fair value. Investors should note this tight alignment between the current market price and our central fair value estimate.

How BMY stacks up against Healthcare

BMY's operational and financial health is categorized as average when compared to its peers within the broader Healthcare sector. This average quality tier is factored into our Monte Carlo model, influencing the distribution of potential fair values. While the stock’s current price of $58.13 aligns closely with the $59.76 fair value, an average quality rating suggests that BMY navigates its competitive landscape with typical sector strengths and challenges. The narrow +2.8% difference between the current price and fair value reflects this balanced outlook.

What this means for investors

Given BMY's Fairly Valued assessment and an average quality tier, investors should consider that the stock's current price of $58.13 offers little immediate cushion or substantial upside based on our P50 fair value of $59.76. While the +2.8% upside is minimal, this alignment signals efficient pricing by the market. Understanding the full range of possibilities requires examining the complete Monte Carlo distribution, including potential downside and bull cases. For a comprehensive view and to track BMY's fair value as new fundamentals are released, sign up for FairCurve to access the full bear/bull distribution and daily updates.